| Identification | Back Directory | [Name]
4-[[[4′-[(4-Nitrobenzoyl)amino][1,1′-biphenyl]-4-yl]carbonyl]amino]-1-naphthalenecarboxylic acid | [CAS]
2101765-83-5 | [Synonyms]
4-[[[4′-[(4-Nitrobenzoyl)amino][1,1′-biphenyl]-4-yl]carbonyl]amino]-1-naphthalenecarboxylic acid | [Molecular Formula]
C31H21N3O6 | [MOL File]
2101765-83-5.mol | [Molecular Weight]
531.52 |
| Chemical Properties | Back Directory | [Boiling point ]
678.031±55.00 °C(Press: 760.00 Torr)(predicted) | [density ]
1.433±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | [form ]
Solid | [pka]
3.754±0.10(predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
DRI-C25441 is a potent blocker of CD40 and CD40L interaction, with an IC50 of 0.36?μM. DRI-C25441 can inhibit the immune response induced by alloantigen[1]. | [IC 50]
CD40: 0.36 μM (IC50) | [References]
[1] Lu H, et, al. Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials. Signal Transduct Target Ther. 2020 Sep 23;5(1):213. DOI:10.1038/s41392-020-00315-3 |
|
|